Aridis Pharmaceuticals, Inc.
ARDS · OTC
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Revenue | $417 | $19,647 | $0 | $0 |
| % Growth | -97.9% | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $417 | $19,647 | $0 | $0 |
| % Margin | 100% | 100% | – | – |
| R&D Expenses | $175 | $4,668 | $5,531 | $7,007 |
| G&A Expenses | $1,111 | $1,310 | $1,814 | $1,626 |
| SG&A Expenses | $1,111 | $1,310 | $1,814 | $1,626 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$417 | $0 | -$1,082 | -$1,213 |
| Operating Expenses | $869 | $5,978 | $6,263 | $7,420 |
| Operating Income | -$869 | $13,669 | -$6,263 | -$7,420 |
| % Margin | -208.4% | 69.6% | – | – |
| Other Income/Exp. Net | $786 | -$1,525 | -$553 | $1,033 |
| Pre-Tax Income | -$83 | $12,144 | -$6,816 | -$6,387 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$83 | $12,144 | -$6,816 | -$6,387 |
| % Margin | -19.9% | 61.8% | – | – |
| EPS | -0.002 | 0.34 | -0.22 | -0.35 |
| % Growth | -100.6% | 254.5% | 37.1% | – |
| EPS Diluted | -0.002 | 0.33 | -0.22 | -0.35 |
| Weighted Avg Shares Out | 37,429 | 36,078 | 30,415 | 18,239 |
| Weighted Avg Shares Out Dil | 37,429 | 36,573 | 30,415 | 18,239 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $3 | $27 | $146 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $59 | $63 | $87 | $100 |
| EBITDA | -$810 | $13,732 | -$6,176 | -$7,320 |
| % Margin | -194.2% | 69.9% | – | – |